Genelux’s (GNLX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Genelux (NASDAQ:GNLX) in a report published on Tuesday,Benzinga reports. HC Wainwright currently has a $30.00 price objective on the stock. HC Wainwright also issued estimates for Genelux’s Q4 2024 earnings at ($0.14) EPS, FY2024 earnings at ($0.84) EPS, Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.72) EPS, FY2026 earnings at ($0.84) EPS, FY2027 earnings at ($0.07) EPS, FY2028 earnings at $1.23 EPS and FY2029 earnings at $2.58 EPS.

Genelux Stock Down 5.3 %

Shares of Genelux stock opened at $3.03 on Tuesday. Genelux has a 52 week low of $1.60 and a 52 week high of $6.50. The business has a 50 day moving average price of $4.05 and a 200-day moving average price of $3.09. The company has a market cap of $104.65 million, a PE ratio of -3.19 and a beta of -1.41.

Institutional Trading of Genelux

Several institutional investors have recently made changes to their positions in the company. Brown Brothers Harriman & Co. boosted its holdings in Genelux by 76.2% during the third quarter. Brown Brothers Harriman & Co. now owns 21,075 shares of the company’s stock worth $50,000 after purchasing an additional 9,114 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Genelux in the 3rd quarter worth approximately $59,000. Geode Capital Management LLC boosted its stake in shares of Genelux by 39.7% in the 3rd quarter. Geode Capital Management LLC now owns 316,160 shares of the company’s stock worth $749,000 after buying an additional 89,854 shares during the last quarter. Apollon Wealth Management LLC grew its holdings in shares of Genelux by 20.4% in the fourth quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock valued at $40,000 after acquiring an additional 2,857 shares in the last quarter. Finally, D.A. Davidson & CO. purchased a new stake in shares of Genelux during the fourth quarter valued at approximately $51,000. Institutional investors own 37.33% of the company’s stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.